FDA Raises Doubts Over Insufficient AtriCure Trial
The U.S. Food and Drug Administration asked an advisory panel Monday to review whether medical device company AtriCure Inc.'s alternative irregular heart rate treatment for atrial fibrillation meets safety and effectiveness...To view the full article, register now.
Already a subscriber? Click here to view full article